1. Home
  2. HOVR vs ANL Comparison

HOVR vs ANL Comparison

Compare HOVR & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Horizon Aircraft Ltd.

HOVR

New Horizon Aircraft Ltd.

HOLD

Current Price

$1.77

Market Cap

103.1M

Sector

Finance

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$1.01

Market Cap

52.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
HOVR
ANL
Founded
2013
2004
Country
Canada
Cayman Islands
Employees
N/A
N/A
Industry
Blank Checks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
103.1M
52.0M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
HOVR
ANL
Price
$1.77
$1.01
Analyst Decision
Strong Buy
Hold
Analyst Count
2
1
Target Price
$6.50
N/A
AVG Volume (30 Days)
1.1M
13.6K
Earning Date
01-13-2026
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$55.08
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.35
$1.00
52 Week High
$4.18
$2.99

Technical Indicators

Market Signals
Indicator
HOVR
ANL
Relative Strength Index (RSI) 47.47 23.81
Support Level $1.16 $1.32
Resistance Level $1.69 $1.59
Average True Range (ATR) 0.17 0.15
MACD 0.06 -0.03
Stochastic Oscillator 77.22 1.69

Price Performance

Historical Comparison
HOVR
ANL

About HOVR New Horizon Aircraft Ltd.

New Horizon Aircraft Ltd is an aerospace Original Equipment Manufacturer that is designing and building a next-generation hybrid electric vertical take-off and landing aircraft for the regional air mobility market. Its aircraft will offer a more efficient way to move people and goods at a regional scale, help to connect remote communities, and advance its ability to deal with an increasing number of climate-related natural disasters such as wildfires, floods, and droughts. The company aims to deliver a hybrid electric 7-seat aircraft, called the Cavorite X7, that can take off and land vertically like and helicopter.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

Share on Social Networks: